Meeting
2016 ASCO Annual Meeting
Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM).
Authors
Max S. Topp
Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
Max S. Topp , Michel Attal , Christian Langer , Philippe Moreau , Thierry Facon , Johannes Düll , Benjamin Hebraud , Carlos Gomez-Roca , Gerd Michael Munzert , Edith Gracien , Gerhard Zugmaier , Hermann Einsele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
EudraCT 2014-004896-22
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS8067)
DOI
10.1200/JCO.2016.34.15_suppl.TPS8067
Abstract #
TPS8067
Poster Bd #
331b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
First Author: Allison Graeter
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2022 ASCO Annual Meeting
Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.
First Author: Guoqing Cao
Poster
2022 ASCO Annual Meeting
Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML.
First Author: Todd Michael Cooper